Trial Sponsors Urged to Get Early U.S. FDA Approval of PROs
Drug trial sponsors developing patient-reported outcome (PRO) measures should seek U.S. Food and Drug Administration (FDA) qualification for them prior to engaging in clinical trials, and should use the measures to gauge quality of life, Janet Woodcock, director of the U.S. Center for Drug Evaluation and Research, advises.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.